-
Two-stage approach for risk estimation of fetal trisomy 21 and other aneuploidies using computational intelligence systems.
Neocleous AC, Syngelaki A, Nicolaides KH, Schizas CN.
Ultrasound Obstet Gynecol 2018;51:503-508. pdf -
Expanded conventional first trimester screening.
Carmichael JB, Liu HP, Janik D, Hallahan TW, Nicolaides KH, Krantz DA.
Prenat Diagn 2017;37:802-807. pdf -
Fetal right ventricular contraction and relaxation times at 11-13 weeks' gestation by speckle tracking imaging.
Persico N, Fabietti I, Baffero G, Fedele L, Nicolaides KH.
Ultrasound Obstet Gynecol 2014;43:284-90. pdf -
First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM.
Ultrasound Obstet Gynecol 2013;42:41-50. pdf -
Prefrontal space ratio: comparison between trisomy 21 and euploid fetuses in the second trimester.
Sonek J, Molina F, Hiett AK, Glover M, McKenna D, Nicolaides KH.
Ultrasound Obstet Gynecol 2012;40:293-6. -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Turning the pyramid of prenatal care.
Nicolaides KH.
Fetal Diagn Ther 2011;29:183-96. -
First-trimester combined screening for trisomy 21 at 8-13 weeks.
Wright D, Spencer K, Kagan K, Tørring N, Petersen O, Christou A, Kallikas J, Nicolaides K.
Ultrasound Obstet Gynecol 2010;36:404-11. -
Two-stage first-trimester screening for trisomy 21 by ultrasound assessment and biochemical testing.
Kagan K, Staboulidou I, Cruz JJ, Wright D, Nicolaides K.
Ultrasound Obstet Gynecol 2010;36:542-7. -
Prospective validation of first-trimester combined screening for trisomy 21.
Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2009;34:14-8. -
Effect of deviation of nuchal translucency measurements on the performance of screening for trisomy 21.
Kagan KO, Wright D, Etchegaray A, Zhou Y, Nicolaides KH.
Ultrasound Obstet Gynecol 2009;33:657-64. -
Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;31:618-24. -
Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation.
Kagan KO, Anderson JM, Anwandter G, Nekrasova K, Nicolaides KH.
Prenat Diagn 2008;28:1209-13. -
Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH.
Hum Reprod 2008;23:1968-75. -
Choroid plexus cyst, intracardiac echogenic focus, hyperechogenic bowel and hydronephrosis in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
Dagklis T, Plasencia W, Maiz N, Duarte L, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;31:132-5. -
Aberrant right subclavian artery at 11 + 0 to 13 + 6 weeks of gestation in chromosomally normal and abnormal fetuses.
Borenstein M, Cavoretto P, Allan L, Huggon I, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;31:20-4. -
First-trimester screening for trisomy 21 using nuchal translucency and nasal bone evaluations in a selected and an unselected population.
Sonek J, Cicero S, Nicolaides K.
Am J Obstet Gynecol 2007;196:19. -
Some thoughts on the true value of ultrasound.
Nicolaides KH.
Ultrasound Obstet Gynecol 2007;30:671-4. -
Sonographic screening for trisomy 13 at 11 to 13(+6) weeks of gestation.
Papageorghiou AT, Avgidou K, Spencer K, Nix B, Nicolaides KH.
Am J Obstet Gynecol 2006;194:397-401. -
Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O, Auer M, Gerovassili A, Spencer K, Nicolaides KH.
Ultrasound Obstet Gynecol 2006;27:151-5.